NCT00706732CompletedPhase 1
A Single-Site, Phase I/II, Double Blinded, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Adult Volunteers 65 Years of Age or Older
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- AlphaVax, Inc.
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Evaluate the safety of AVX502 in healthy adult volunteers 65 years of age or older via the frequency of systemic reactogenicity events, local vaccine reactions and Adverse Events
Study Overview
Brief Summary
The objective of this study is to evaluate the safety of the vaccine and the immune response to the vaccine in healthy adult volunteers 65 years of age or older. Volunteers will be assigned by randomization to receive either the vaccine or an inactive substance (placebo) by injections in the arm on two occasions over one month. The study will last approximately 10 months and will have a total of 7 visits.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 65 Years to — (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 65 years of age or older
- •Good general health without significant physical examination findings or clinically significant abnormal laboratory results
- •Available to participate for entire study period
- •Acceptable laboratory parameters
- •Willingness to have blood stored for up to 10 years for use in additional assays to evaluate immune responses to influenza or the alphavirus vector if such assays become available
- •Willingness to refrain from donating blood while participating in the study
- •Willingness to delay receipt of 2008-2009 licensed influenza vaccination until after completing study visit 6 procedures (study week 8)
- •Signed inform consent obtained before screening and before enrollment
Exclusion Criteria
- •Venous access deemed inadequate for th phlebotomy demands of the study
- •Receipt of any other vaccine within 30 days prior to enrollment
- •Use of any investigational agent within 30 days prior to enrollment
- •Receipt of immunoglobulin or other blood products within 60 days prior to enrollment
- •Use of cytotoxic medications within 6 months prior to enrollment
- •Use of systemic corticosteroids within 6 months prior to enrollment (except that participants who have completed a course of prednisone, at up to 20 mg per day for up to 7 days, at least 1 month prior to enrollment are eligible for enrollment)
- •History of serious adverse reactions to any vaccines, including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, or abdominal pain
- •History of autoimmune disease or splenectomy
- •History of malignancy within the last 3 years (except that participants with a diagnosis of basal cell carcinoma of the skin are eligible for enrollment)
- •Psychiatric condition that may interfere with the ability to comply with the protocol requirements or to understand informed consent. Specifically excluded are persons with history of psychosis within the past 3 years or history of suicidal attempt or gesture within the past 3 years.
- •History of medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months
- •Any condition which leads the investigator to believe that the particpant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for further participation.
Arms & Interventions
C2
Placebo Comparator
Intervention: Placebo (Biological)
C1
Placebo Comparator
Intervention: Placebo (Biological)
T2
Active Comparator
Intervention: AVX502 (Biological)
T1
Active Comparator
Intervention: AVX502 (Biological)
Outcomes
Primary Outcomes
Evaluate the safety of AVX502 in healthy adult volunteers 65 years of age or older via the frequency of systemic reactogenicity events, local vaccine reactions and Adverse Events
Time Frame: 28 weeks
Secondary Outcomes
- Evaluate the immunogenicity of AVX502 in healthy adult volunteers 65 years of age and older via serum antibody concentration(4 weeks after second dose of vaccine)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.Infection by Streptococcus Group BNCT02459262Minervax ApS240
Completed
Phase 1
H5N1 (Clade 2) Vaccination of Adults and ElderlyInfluenzaNCT00680069National Institute of Allergy and Infectious Diseases (NIAID)517
Completed
Phase 1
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's DiseaseAlzheimer DiseaseDementia AlzheimersDementia, MildNCT05328115Alzinova AB33
Completed
Phase 3
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersInfluenzaNCT01987011Green Cross Corporation420
Completed
Phase 1
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage II Breast CancerStage IIIC Breast CancerHER2-positive Breast CancerMale Breast CancerNCT01632332Mayo Clinic22